ТИРОНЕТ – все о щитовидной железе Для специалистов Журнал Тиронет Архив журнала 2004 год № 1-2

Использование рекомбинантного человеческого ТТГ при заболеваниях щитовидной железы

С. Толаней (S. Tolaney) ассистент в госпитале университета Джона Хопкинса
П. Ладенсон (P.W. Ladenson) - директор отдела эндокринологии и метаболизма и центра по диагностике и лечения опухолей щитовидной железы медицинского института Джона Хопкинса (Балтимор, Мэриленд, США)

ЛИТЕРАТУРА

  1. Seidlin S., Oshry E., Yallow A.A. Spontaneous and experimentally induced uptake of radioactive iodine in metastases from thyroid carcinoma. // J Clin Endocrinol Metab — 1948 — Vol. 8. — P. 423 — 425.
  2. Ramirez L., Braverman L.E., White B., Emerson C.H. Recombinant human thyrotropin is a potent stimulator of thyroid function in normal subjects. // J Clin Endocrinol Metab — 1997 — Vol. 82. — P. 2836 — 2839.
  3. Hormone Drugs. Proceeding from the FDA-USP workshop on drug and reference standards for insulins, somatotropins, and thyroid-axis hormones, Bethesda, MD, Rockville, MD: United States Pharmacopeial Convention; May 19 — 21. — 1982 — P. 583.
  4. Fiddes J.C., Goodman H.M. Isolation, cloning, and sequence analysis of the cDNA for the alpha-subunit of human chorionic gonadotropin. // Nature — 1979 — Vol. 281. — P. 351 — 356.
  5. Wondisford F.E., Radovick S., Moates J.M., et al. Isolation and characterization of the human thyrotropin в-subunit gene. // J Biol Chem — 1988 — Vol. 263. — P. 12538 — 12542.
  6. Wondisford F.E., Usala S.J., DeCherney G.S., et al. Cloning of the human thyrotropin в-subunit gene and transient expression of biologically active human thyrotropin after gene transfection. // Mol Endocrinol — 1988 — Vol. 2. — P. 32 — 39.
  7. Thoktakura N.K., Desai R.K., Bates L.G., et al. Biological activity and metabolic clearance of a recombinant human thyrotropin produced in Chinese hamster ovary cells. // Endocrinology — 1991 — Vol. 128. — P. 341 — 348.
  8. Huber G.H., Fong P., Concepcion E.S., Davies T.F. Recombinant human thyroid-stimulating hormone: initial bioactivity assessment using human fetal thyroid cells. // J Clin Endocrinol Metab — 1991 — Vol. 72. — P. 1328-1331.
  9. Braverman L.E., Pratt B.M., Ebner S., Longcope C. Recombinant human thyrotropin stimulates thyroid function and radioactive iodine uptake in the rhesus monkey. // J Clin Endocrinol Metab — 1992 — Vol. 74. — P. 1135 — 1139.
  10. Robbins R.J., Robbins A.K. Recombinant human thyrotropin and thyroid cancer management. // J Clin Endocrinol Metab — 2003 — Vol. 88. — P. 1933 — 1938.
  11. Ries L., Eisner M.P., Kosary C.L., et al. 2000 SEER Cancer Statistics Review, 1973-1997. Bethesda, MD: National Cancer Institute
  12. Basaria M., Graf H., Cooper D.S. Use of recombinant thyrotropin in the follow-up of patients with differentiated thyroid cancer. // Am J Med. — 2002 — Vol. 112. — P. 721 — 725.
  13. Mazzaferri E.L., Jhiang S.M. Long-term impact of initial surgical and medical therapy on papillary and follicular thyroid cancer. // Am J Med — 1994 — Vol. 97. — P. 418 — 428.
  14. Schneider A.B., Line B.R., Goldman J.M., Robbins J. Sequential serum thyroglobulin determination, 131-I scans, and 131-I uptakes after triiodothyronine withdrawal in patients with thyroid cancer. // J Clin Endocrinol Metab — 1981 — Vol. 53. — P. 1199 — 1206.
  15. Goldberg LD, Ditchek NT. Thyroid carcinoma with spinal cord compression. // JAMA — 1981 — Vol. 245. — P. 953 — 954.
  16. Meier C.A., Braverman L.E., Ebner S.A., et al. Diagnostic use of recombinant human thyrotropin in patients with thyroid carcinoma (phase I/II study). // J Clin Endocrinol Metab — 1994 — Vol. 78. — P. 188 — 196.
  17. Ladenson P.W., Braverman L.E., Mazzaferri E.L., et al. Comparison of administration of recombinant human thyrotropin with withdrawal of thyroid hormone for radioactive iodine scanning in patients with thyroid carcinoma. // N Engl J Med — 1997 — Vol. 337. — P. 888 — 896.
  18. Haugen B.R., Pacini F., Reiners C., et al. A comparison of recombinant thyrotropin and thyroid hormone withdrawal for the detection of thyroid remnant or cancer. // J Clin Endocrinol Metab — 1999 — Vol. 84. — P. 3877 — 3885.
  19. Robbins R.J., Tuttle R.M., Sharaf R.N., et al. Preparation by recombinant human thyrotropin or thyroid hormone withdrawal are comparable for the detection of residual differentiated thyroid carcinoma. // J Clin Endocrinol Metab — 2001 — Vol. 86. — P. 619 — 625.
  20. Robbins R.J., Chon J.T., Fleisher M., et al. Is the serum thyroglobulin response to recombinant human thyrotropin sufficient, by itself, to monitor for residual thyroid carcinoma? // J Clin Endocrinol Metab — Vol. 2002 — Vol. 87. — P. 3242-3247.
  21. Pacini F., Molinaro E., Lippi F., et al. Prediction of disease status by recombinant human TSHstimulated serum thyroglobulin in the postsurgical followup of differentiated thyroid carcinoma. // J Clin Endocrinol Metab — 2001 — Vol. 86. — P. 5686 — 5690.
  22. Mazzaferri E.L., Robbins R.J., Spencer C.A., et al. A consensus report of the role of serum thyroglobulin as a monitoring method for low-risk patients with papillary thyroid carcinoma. // J Clin Endocrinol Metab — 2003 — Vol. 88. — P. 1433 — 1441.
  23. Wang W., Macapinlac H., Larson S.M., et al. [18F]-2-Fluoro-2-deoxy-dglucose positron emission tomography localizes residual thyroid cancer in patients with negative diagnostic 131I whole body scans and elevated serum thyroglobulin levels. // J Clin Endocrinol Metab — 1999 — Vol. 84. — P. 2291 — 2302.
  24. Moog F., Linke R., Mathey N., et al. Influence of thyroid-stimulating hormone levels on uptake of FDG in recurrent and metastatic differentiated thyroid carcinoma. // J Nucl Met — 2000 — Vol. 41. — P. 1989 — 1995.
  25. Petrich T., Borner A.F., Otto D., et al. Influence of rhTSH on [18F]-fluorodeoxyglucose uptake by differentiated thyroid carcinoma. // Eur J Nucl Med. — 2000 — Vol. 29. — P. 641 — 647.
  26. Robbins R.J., Larson S.M., Sinha N., et al. A retrospective review of the effectiveness of recombinant human TSH as a preparation for radioiodine thyroid remnant ablation. // J Nucl Med — 2002 — Vol. 43. — P. 1482 — 1488.
  27. Robbins R.J., Tuttle R.M., Sonenberg M., et al. Radioiodine ablation of thyroid remnants after preparation with recombinant human thyrotropin. // Thyroid — 2001 — Vol. 11. — P. 865 — 869.
  28. Pacini F., Molinaro E., Castagna M.G., et al. Ablation of thyroid residues with 30 mci 131I: a comparison in thyroid cancer patients prepared with recombinant human TSH or thyroid hormone withdrawal. // J Clin Endocrinol Metab — 2002 — Vol. 87. — P. 4063 — 4068.
  29. Barbaro D., Boni G., Meucci G., et al. Radioiodine treatment with 30 mCi after recombinant human thyrotropin stimulation in thyroid cancer: effectiveness for postsurgical remnants ablation and possible role of iodine content in L-thyroxine in the outcome of ablation. // J Clin Endocrinol Metab. — 2003 — Vol. 88. — P. 4110 — 4115.
  30. Rudavsky A.Z., Freeman L.M. Treatment of scan-negative, thyroglobulin-positive metastatic thyroid cancer using radioiodine 131I and recombinant human thyroid stimulating hormone. // J Clin Endocrinol Metab — 1997 — Vol. 82. — P. 11 — 14.
  31. Chiu A.C., Delpassand E.S., Sherman S.I. Prognosis and treatment of brain metastases in thyroid carcinoma. // J Clin Endocrinol Metab — 1997 — Vol. 82. — P. 3637 — 3642.
  32. Perros P. Recombinant human thyroid-stimulating hormone (rhTSH) in the radioablation of well-differentiated thyroid cancer: Preliminary therapeutic experience. // J Endocrinol Invest — 1999 — Vol. 22. — P. 30 — 34.
  33. Luster M., Lassman M., Haenscheid H., et al. Use of recombinant human thyrotropin before radioiodine therapy in patients with advanced differentiated thyroid carcinoma. // J Clin Endocrinol Metab — 2000 — Vol. 85. — P. 3640 — 3645.
  34. Lippi F., Capezzone M., Angelini F., et al. Radioiodine treatment of metastatic differentiated thyroid cancer in patients on L-thyroxine, using recombinant human TSH. // Eur J Endocrinol — 2001 — Vol. 144 — P. 5 — 11.
  35. Huysmans D.A., Nieuwlaat W.A., Erdtsieck R.J., et al. Administration of a single low dose of recombinant human thyrotropin significantly enhances thyroid radioiodide uptake in nontoxic nodular goiter. // J Clin Endocrinol Metab — 2000 — Vol. 85. — P. 3592 — 3596.
  36. Nieuwlaat W.A., Hermus A.R., Sivro-Prndelf F., et al. Pretreatment with recombinant human TSH changes the regional distribution of radioiodine on thyroid scintigrams of nodular goiters. // J Clin Endocrinol Metab — 2001 — Vol. 86. — P. 5330-5336.
  37. Nieuwlaat W.A., Huysmans D.A., Can Den Bosch H.C., et al. Pretreatment with a single, low dose of recombinant human thyrotropin allows dose reduction of radioiodine therapy in patients with nodular goiter. // J Clin Endocrinol — 2003 — Vol. 88. — P. 3121 — 3129.
  38. Duick D.S., Baskin H.J. Utility of recombinant human thyrotropin for augmentation of radioioidine uptake and treatment of nontoxic and toxic multinodular goiter. // Endocr Pract — 2003 — Vol. 9. — P. 204 — 209.
  39. Lawrence J.E., Emerson C.H., Sullaway S.L., et al. The effect of recombinant human TSH on the thyroid 123I uptake in iodide treated normal subjects. // J Clin Endocrinol Metab — 2001 — Vol. 86. — P. 437 — 440.
  40. Braga M., Ringel M.D., Cooper D.S. Sudden enlargement of local recurrent thyroid tumor after recombinant human TSH administration. //J Clin Endocrinol Metab — 2001 — P. 5148 — 5151.
  41. Vargas G.E., Uy H., Bazan C., et al. Hemiplegia after thyrotropin in a hypothyroid patient with thyroid carcinoma metastatic to the brain. // J Clin Endocrinol Metab — 1999 — Vol. 84. — P. 3877 — 3885.
  42. Biondi B., Palmierei E.A., Pagano L., et al. Cardiovascular safety of acute recombinant human thyrotropin administration to patients monitored for differentiated thyroid cancer. // J Clin Endocrinol Metab — 2003 — Vol. 88. — P. 211 - 214
  43. Thyroid Cancer Task Force: AACE/AAES medical/surgical guidelines for clinical practice: management of thyroid carcinoma. American Association of Clinical Endocrinologists. American College of Endocrinology. // Endocr Pract — 2001 - Vol. 7. — P. 202.
  44. Basaria M., Graf H., Cooper D.S. The use of recombinant thyrotropin the follow-up of patients with differentiated thyroid cancer. // Am J Med — 2002 — Vol. 112. — P. 721 — 725.
  45. NCCN Clinical Practice Guidelines in Oncology, May 2003. www.nccn.org
  46. David A., Blotta A., Bondanelli M., et al. Serum thyroglobulin concentrations and 131i whole-body scan results in patients with differentiated thyroid carcinoma after administration of recombinant human thyroid-stimulating hormone. // J Nucl Med — 2001 — Vol. 42. — P. 1470 — 1475.
  47. Haugen B.R., Ridgway E.D., McLaughlin B.A., et al. Clinical comparison of whole-body radioiodine scan and serum thyroglobulin after stimulation with recombinant human thyrotropin. // Thyroid — 2002 — Vol. 12. — P. 37 — 43.
  48. Mazzaferri E., Kloos R.T. Is Diagnostic Iodine-131 Scanning with recombinant human TSH useful in the follow- up of differentiated thyroid cancer after thyroid ablation? // J Clin Endocrinol Metab — 2002 — Vol. 87. — P. 1490 — 1498.
  49. Wartofsky L. and the rhTSH-Stimulated Thyroglobulin Study Group. Management of low-risk well-differentiated thyroid cancer based on thyroglobulin measurement after recombinant human thyrotropin. // Thyroid — 2002 — Vol. 12. — P. 583 — 590.

Для специалистов

Новостная рассылка

Поиск